Related references
Note: Only part of the references are listed.Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan et al.
ONCOLOGIST (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Trop2 deal heats up antibody-drug conjugate space in cancer
Catherine Shaffer
NATURE BIOTECHNOLOGY (2021)
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer
Madoka Iwase et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Destabilization of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway as a potential treatment for triple-negative breast cancer
Won-Ji Ryu et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
Soong June Bae et al.
SCIENTIFIC REPORTS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Begona Pineda et al.
CLINICAL EPIGENETICS (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer
Dilan A. Patel et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Pascal Jezequel et al.
BREAST CANCER RESEARCH (2019)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Tiffany A. Traina et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Yuka Asano et al.
CANCERS (2017)
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
Debora Basile et al.
CANCER TREATMENT REVIEWS (2017)
Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
Erik Hilborn et al.
BRITISH JOURNAL OF CANCER (2016)
Targeting the androgen receptor in triple-negative breast cancer
Ayca Gucalp et al.
CURRENT PROBLEMS IN CANCER (2016)
Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage
Valeria Fernandez Vallone et al.
DEVELOPMENT (2016)
Androgen receptor signaling pathways as a target for breast cancer treatment
Elisabetta Pietri et al.
ENDOCRINE-RELATED CANCER (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
Ramesh Narayanan et al.
CANCERS (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
Mirco Pistelli et al.
BMC CANCER (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C. U. Cheang et al.
ONCOLOGIST (2015)
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Johnathan Watkins et al.
CANCER DISCOVERY (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Tumor-infiltrating CD8+and FOXP3+lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy
Minoru Miyashita et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
Priyanka Sharma et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Heae Surng Park et al.
MODERN PATHOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
Justin M. Balko et al.
CANCER RESEARCH (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2013)
The role of the androgen receptor in triple-negative breast cancer
Payal D. Shah et al.
WOMENS HEALTH (2013)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
Justin M. Balko et al.
NATURE MEDICINE (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade
Kristi Baker et al.
HISTOPATHOLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Expression of androgen receptors in primary breast cancer
S. Park et al.
ANNALS OF ONCOLOGY (2010)
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Hannah Harrison et al.
CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
Leo A. Niemeier et al.
MODERN PATHOLOGY (2010)
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
Rafael Cubas et al.
MOLECULAR CANCER (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
Ashok R. Venkitaraman
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
Theresa A. DiMeo et al.
CANCER RESEARCH (2009)
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
Maximina H. Yun et al.
NATURE (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
Deann P. Atchley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
BRCA1 dysfunction in sporadic basal-like breast cancer
N. C. Turner et al.
ONCOGENE (2007)
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer
Takeharu Yamanaka et al.
ONCOLOGY (2007)
Basal-like breast cancer and the BRCA1 phenotype
N. C. Turner et al.
ONCOGENE (2006)
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells
Suling Liu et al.
CANCER RESEARCH (2006)
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
Francois Bertucci et al.
CANCER RESEARCH (2006)
Breast cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for tumor progression
MM Queen et al.
CANCER RESEARCH (2005)
Chemopotentiation by PARP inhibitors in cancer therapy
L Tentori et al.
PHARMACOLOGICAL RESEARCH (2005)
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles
E Matros et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining
M Audebert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8
JE De Larco et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade
SL Ding et al.
BRITISH JOURNAL OF CANCER (2004)
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
WD Foulkes et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
